BIOMAT Database Logo BIOMAT Database Logo

Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion. 1993

H Kobayashi, and H Ohi, and H Shinohara, and M Sugimura, and T Fujii, and T Terao, and M Schmitt, and L Goretzki, and N Chucholowski, and F Jänicke
Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, Shizuoka, Japan.

Single-chain urokinase-type plasminogen activator (pro-uPA) is bound to a specific surface receptor on ovarian cancer HOC-I cells that is incompletely saturated. Saturation of uncovered receptors by uPA polypeptides with intact amino-terminal fragment (ATF) derived from pro-uPA by limited proteolysis (human leucocyte elastase [HLE] or V8 protease) has been studied. HOC-I cells preferentially invaded reconstituted basement membranes in a time- and plasminogen-dependent manner. This process was inhibitable by preincubation with uPA polypeptides in the medium at levels which suggested that complete saturation of cell surface uPA receptors occurred. This result indicates that occupation of uPA receptors by enzymatically inactive uPA fragments or prevention of rebinding of pro-uPA synthesised by tumour cells to the receptors specifically reduces the invasion of the tumour cells through basement membranes in vitro.

UI MeSH Term Description Entries
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D010196 Pancreatic Elastase A protease of broad specificity, obtained from dried pancreas. Molecular weight is approximately 25,000. The enzyme breaks down elastin, the specific protein of elastic fibers, and digests other proteins such as fibrin, hemoglobin, and albumin. EC 3.4.21.36. Elastase,Pancreatopeptidase,Elastase I,Pancreatic Elastase I,Elastase I, Pancreatic,Elastase, Pancreatic
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011956 Receptors, Cell Surface Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands. Cell Surface Receptor,Cell Surface Receptors,Hormone Receptors, Cell Surface,Receptors, Endogenous Substances,Cell Surface Hormone Receptors,Endogenous Substances Receptors,Receptor, Cell Surface,Surface Receptor, Cell
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D004591 Electrophoresis, Polyacrylamide Gel Electrophoresis in which a polyacrylamide gel is used as the diffusion medium. Polyacrylamide Gel Electrophoresis,SDS-PAGE,Sodium Dodecyl Sulfate-PAGE,Gel Electrophoresis, Polyacrylamide,SDS PAGE,Sodium Dodecyl Sulfate PAGE,Sodium Dodecyl Sulfate-PAGEs
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

H Kobayashi, and H Ohi, and H Shinohara, and M Sugimura, and T Fujii, and T Terao, and M Schmitt, and L Goretzki, and N Chucholowski, and F Jänicke
Amino-terminal fragment of urokinase-type plasminogen activator inhibits its plasminogen activation.
April 2002, Thrombosis research,
H Kobayashi, and H Ohi, and H Shinohara, and M Sugimura, and T Fujii, and T Terao, and M Schmitt, and L Goretzki, and N Chucholowski, and F Jänicke
Solution structure of the amino-terminal fragment of urokinase-type plasminogen activator.
April 1994, Biochemistry,
H Kobayashi, and H Ohi, and H Shinohara, and M Sugimura, and T Fujii, and T Terao, and M Schmitt, and L Goretzki, and N Chucholowski, and F Jänicke
Amino-terminal fragment of urokinase-type plasminogen activator inhibits HIV-1 replication.
June 2001, Biochemical and biophysical research communications,
H Kobayashi, and H Ohi, and H Shinohara, and M Sugimura, and T Fujii, and T Terao, and M Schmitt, and L Goretzki, and N Chucholowski, and F Jänicke
Protein expression and preliminary crystallographic analysis of amino-terminal fragment of urokinase-type plasminogen activator.
September 2006, Protein expression and purification,
H Kobayashi, and H Ohi, and H Shinohara, and M Sugimura, and T Fujii, and T Terao, and M Schmitt, and L Goretzki, and N Chucholowski, and F Jänicke
Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
October 2005, Human gene therapy,
H Kobayashi, and H Ohi, and H Shinohara, and M Sugimura, and T Fujii, and T Terao, and M Schmitt, and L Goretzki, and N Chucholowski, and F Jänicke
A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis.
February 2005, Journal of cancer research and clinical oncology,
H Kobayashi, and H Ohi, and H Shinohara, and M Sugimura, and T Fujii, and T Terao, and M Schmitt, and L Goretzki, and N Chucholowski, and F Jänicke
Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
November 2002, Oncogene,
H Kobayashi, and H Ohi, and H Shinohara, and M Sugimura, and T Fujii, and T Terao, and M Schmitt, and L Goretzki, and N Chucholowski, and F Jänicke
Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor.
August 2000, British journal of cancer,
H Kobayashi, and H Ohi, and H Shinohara, and M Sugimura, and T Fujii, and T Terao, and M Schmitt, and L Goretzki, and N Chucholowski, and F Jänicke
Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling.
November 2003, The Journal of biological chemistry,
H Kobayashi, and H Ohi, and H Shinohara, and M Sugimura, and T Fujii, and T Terao, and M Schmitt, and L Goretzki, and N Chucholowski, and F Jänicke
Effect of the cyanogen-bromide-2 fragment of fibrinogen on plasminogen activation by single-chain urokinase-type plasminogen activator.
July 1987, European journal of biochemistry,
Copied contents to your clipboard!